Table 3 Linaclotide usage
From: Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
Clinical variable | High-dose Linaclotide (n = 13) | Low-dose Linaclotide (n = 18) | p-value |
|---|---|---|---|
Frequency, doses per week, median (IQR) | 7 (7–7) | 7 (1–7) | 0.774 |
Average daily dose in mcg, mean (SD) | 273 (32) | 137 (24) | < 0.0001 |
Side effect | |||
Abdominal pain, % (n) | 15 (2/13) | 11 (2/18) | 1.0000 |
Diarrhea, cramping, or bloating, % (n) | 15 (2/13) | 50 (9/18) | 0.0656 |
Nausea, % (n) | 8 (1/13) | 6 (1/18) | 1.0000 |
Unspecified/did not tolerate, % (n) | 8 (1/13) | 6 (1/18) | 1.0000 |
Length of treatment in months (SD) | 21 (12–50) | 13.5 (7–27) | 0.1382 |
Weight change on linaclotide, lb, median (IQR) | 0.8 (− 3.8 to 1.4) | − 0.6 (− 3.7 to 1.4) | 0.5914 |